| Trial ID: | L4317 |
| Source ID: | NCT01976858
|
| Associated Drug: |
Pex168
|
| Title: |
A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: PEX168
|
| Outcome Measures: |
Primary: To determine serum concentrations of PEX168, 8 weeks | Secondary: To determin HbA1c levels of PEX168, 8 weeks | Other: To assess number of participants with Adverse Events as a Measure of Safety and To assess number of participants with Adverse Events as a Measure of Safety and Tolerability, 8 weeks
|
| Sponsor/Collaborators: |
Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Collaborators: Beijing Tongren Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2011-06
|
| Completion Date: |
2011-12
|
| Results First Posted: |
|
| Last Update Posted: |
2013-11-06
|
| Locations: |
Beijing tongren hospital, Beijing, Beijing, China
|
| URL: |
https://clinicaltrials.gov/show/NCT01976858
|
